Join to view full profile
450 Brookline AveD830Boston, MA 02215
Phone+1 617-632-3141
Fax+1 617-632-2934
Dr. Kufe is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
George Washington UniversityResidency, Internal Medicine, 1975 - 1977
Beth Israel Deaconess Medical CenterInternship, Transitional Year, 1970 - 1971
University of Rochester School of Medicine and DentistryClass of 1970
Certifications & Licensure
MA State Medical License 1977 - 2027
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 1982
Clinical Trials
Publications & Presentations
PubMed
- 1 citationsM1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors.Shinkichi Takamori, Naoki Haratake, Atrayee Bhattacharya, Hiroki Ozawa, Keisuke Shigeta
Oncogene. 2026-10-01 - Evolution ofDuring Retrotransposon Expansion as a Potential Adaptation Exploited in Human Cancer.Naoki Haratake, Shinkichi Takamori, Keisuke Shigeta, Donald Kufe
International Journal of Molecular Sciences. 2026-07-09 - M1C IS NECESSARY FOR DARAXONRASIB RESISTANCE OF NSCLC KRAS(G12C) MUTANT CELLS.Shinkichi Takamori, Naoki Haratake, Kentaro Nonaka, Mai Moriya, Atrayee Bhattacharya
Biorxiv. 2026-06-23
Journal Articles
- Targeting the Human MUC1-C Oncoprotein with an Antibody-Drug ConjugateQing Zhao, Donald Kufe, The Journal of Clinical Investigation
Abstracts/Posters
- Development of Novel Second Generation DC/Tumor Fusion Vaccine in LymphomaDonald Kufe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Transcriptome Sequencing Demonstrates Unique Signature Associated with Durable Clinical Response to DC/AML Fusion VaccineDonald Kufe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- T Cells Educated By DC/AML Fusions in the Context of 4-1BB Costimulation As a Potent Strategy for Adoptive Cellular TherapyDonald Kufe, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Hillstream BioPharma Signs an Exclusive Option Agreement to Advance Next-Generation Anti-MUC1-C Agents for Drug Resistant CancersJanuary 31st, 2023
Grant Support
- Combining CDK7 and MUC1-C inhibition to target different subtypes of small cell lung cancerNEW YORK UNIVERSITY SCHOOL OF MEDICINE2024–2029
- Targeting the MUC1-C Oncoprotein in Triple-Negative Breast CancerDANA-FARBER CANCER INST2002–2029
- Extension of the Dana Farber Harvard Cancer Center Consortium for the ETCTNDANA-FARBER CANCER INST2014–2027
- MUC1-C is a target for advancing immunotherapy of non-small cell lung cancerDANA-FARBER CANCER INST2024–2026
- Targeting MUC1-C with an antibody drug conjugate for the therapy of advanced prostate cancerDANA-FARBER CANCER INST2022–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: